Premium
Induction of protective and therapeutic antitumour immunity using a novel tumour‐associated antigen‐specific DNA vaccine
Author(s) -
Sun Wenxin,
Qian Haili,
Zhang Xueyan,
Zhou Chunxia,
Liang Xiao,
Wang Dongmei,
Fu Ming,
Ma Wenbo,
Zhang Shuren,
Lin Chen
Publication year - 2006
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/j.1440-1711.2006.01453.x
Subject(s) - dna vaccination , immunity , antigen , dna , immunology , virology , medicine , biology , immune system , cancer research , immunization , genetics
DNA vaccination has become an attractive immunization strategy against cancer. However, a major problem of DNA vaccination is its limited potency to be taken up by the antigen‐presenting cells. In contrast, loss of immunogenic epitopes of tumour cells has urged the development of vaccines against multiple epitopes. In this study, we developed a novel strategy for the APC to efficiently cross‐present a fusion tumour antigen, which contains both MHC class I‐restricted and class II‐restricted T‐cell epitopes from Her‐2/neu and p53 in a cognate manner. The N‐terminus of the fusion Her‐2/neu, p53 protein was linked to the sequence encoding for human secondary lymphoid‐tissue chemokine for secretion and chemokinesis, and the C‐terminus of the fusion protein was linked to a cell‐binding domain of IgG (Fc portion, the cell‐binding domain of IgG) for receptor‐mediated internalization. Here, we show that the introduction of fused‐gene DNA vaccine by gene gun reduced the size of established tumours and prolonged the lifespan of tumour‐bearing mice. Results show that this DNA vaccination strategy can broadly enhance the antigen‐specific cellular and humoral immune responses. This vaccine is capable of inducing adaptive immunity and may provide a novel, generic design for the development of therapeutic and preventive DNA vaccines.